Kim N.

Research interests

Publications

• Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

  Journal of Clinical Oncology · 2023 · 10.1200/jco.22.01649

• Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2107322

• Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study

  Journal of Clinical Oncology · 2021 · 10.1200/jco.20.03488

• Olaparib for Metastatic Castration-Resistant Prostate Cancer

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa1911440

• Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

  New England Journal of Medicine · 2020 · 10.1056/nejmoa2022485

• Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019

  European Urology · 2020 · 10.1016/j.eururo.2020.01.012

• The DNA methylation landscape of advanced prostate cancer

  Nature Genetics · 2020 · 10.1038/s41588-020-0648-8

• Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1903835

• Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial

  The Lancet Oncology · 2019 · 10.1016/s1470-2045(19)30082-8

• Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1903307

• Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial

  The Lancet Oncology · 2019 · 10.1016/s1470-2045(19)30688-6

• Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer

  Cancer Discovery · 2018 · 10.1158/2159-8290.cd-17-0937

• Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer

  Cell · 2018 · https://doi.org/10.1016/j.cell.2018.06.039

• Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study

  Journal of Clinical Oncology · 2018 · 10.1200/jco.2017.77.6880

• Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

  New England Journal of Medicine · 2017 · 10.1056/nejmoa1704174

• Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer

  JNCI Journal of the National Cancer Institute · 2017 · 10.1093/jnci/djx118

• Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

  Journal of Clinical Oncology · 2016 · 10.1200/jco.2015.64.2702

• Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

  Journal of Clinical Oncology · 2016 · 10.1200/jco.2015.65.7270

• Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer

  JAMA Oncology · 2016 · 10.1001/jamaoncol.2016.0494

• Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer

  Clinical Cancer Research · 2015 · 10.1158/1078-0432.ccr-14-2666

• Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

  The Lancet Oncology · 2012 · 10.1016/s1470-2045(12)70379-0

• Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

  New England Journal of Medicine · 2012 · 10.1056/nejmoa1207506

• Abiraterone and Increased Survival in Metastatic Prostate Cancer

  New England Journal of Medicine · 2011 · 10.1056/nejmoa1014618

• Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2008.21.4809

• Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

  New England Journal of Medicine · 2004 · 10.1056/nejmoa040720

Current projects

No projects listed.